Two phase 2b studies in atopic dermatitis and alopecia areata reported positive outcomes, demonstrating clinically meaningful ...
Earnings call Nektar ended 2025 with $245.8M in cash and no debt, bolstered by an additional $476M in early 2026. REZPEG advanced to phase 3 in atopic dermatitis with phase 3 initiation set for June ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果